Metadoze IPR 850 Tablet SR

Introduction

Metadoze IPR 850 Tablet SR is a widely prescribed oral medication primarily used to manage blood sugar levels in individuals with type 2 diabetes mellitus. It belongs to the biguanide class of medicines and is formulated as a Sustained Release (SR) tablet. This "Initial Pulse Release" (IPR) technology ensures that the medication is released gradually into the bloodstream, providing more consistent glucose control throughout the day while minimizing common stomach-related side effects. It is often the first line of treatment when diet and exercise alone are insufficient to maintain healthy blood sugar levels.

Uses of Metadoze IPR 850 Tablet SR

• Management of Type 2 Diabetes Mellitus in adults and children (usually over 10 years).
• Assisting in the prevention of long-term diabetes complications like kidney damage and nerve problems.
• Off-label use in managing Polycystic Ovary Syndrome (PCOS) to improve insulin sensitivity.
• Helping to control blood sugar levels when lifestyle changes are not enough.

How Metadoze IPR 850 Tablet SR Works

This medication works by improving how your body handles insulin. It does not increase insulin production; instead, it reduces the amount of glucose (sugar) produced by the liver and slows down the absorption of sugar from the intestines. Additionally, it increases the sensitivity of your body’s muscles to insulin, allowing them to use glucose more effectively for energy, which naturally lowers the sugar levels in your blood.

Benefits of Metadoze IPR 850 Tablet SR

• Provides long-lasting blood sugar control due to its sustained-release mechanism.
• Unlike some other diabetes medications, it carries a lower risk of causing hypoglycemia (dangerously low blood sugar).
• It is often weight-neutral or may even assist in modest weight loss.
• Reduces the risk of cardiovascular complications associated with chronic high blood sugar.

How to Take Metadoze IPR 850 Tablet SR

Always follow your doctor’s specific instructions regarding dosage. Generally, this tablet should be swallowed whole with a glass of water; do not crush, chew, or break it, as this destroys the sustained-release property. It is best taken with a meal to reduce the chances of an upset stomach. Consistency is key, so try to take it at the same time every day to maintain a steady level of medicine in your body.

Side Effects of Metadoze IPR 850 Tablet SR

• Nausea and vomiting.
• Diarrhea or stomach pain.
• Loss of appetite or a metallic taste in the mouth.
• Vitamin B12 deficiency (with long-term use).
• Lactic acidosis (a rare but serious condition involving a buildup of acid in the blood).

Safety Advice

• Inform your doctor if you have a history of kidney or liver disease before starting this medication.
• Avoid excessive alcohol consumption while on this drug, as it increases the risk of lactic acidosis.
• Monitor your blood sugar levels regularly as directed by your healthcare provider.
• If you are scheduled for surgery or a scan involving iodine dye, you may need to stop the medicine temporarily.
• Pregnant or breastfeeding women should consult their doctor to weigh the benefits and risks.

Frequently Asked Questions (FAQs)

Q: Can Metadoze IPR 850 Tablet SR cause weight loss?
A: Yes, many patients experience a slight reduction in weight while taking Metformin because it helps regulate insulin and can slightly suppress appetite.

Q: What should I do if I miss a dose?
A: Take it as soon as you remember with food. However, if it is almost time for your next dose, skip the missed one. Do not double the dose to catch up.

Q: Is it safe to drive after taking this medicine?
A: Generally, yes. Metformin alone does not usually cause sleepiness or low blood sugar that would affect driving, but be cautious if you are taking it alongside other diabetes medications.

Q: Why is it called a "Sustained Release" tablet?
A: It is designed to release the drug slowly over several hours. This prevents a sudden spike of medicine in your system and helps reduce stomach discomfort compared to immediate-release versions.